Preclinical Evaluation Of Vaccines And Antivirals In RSV Challenge Rodent Models

By Nagendra Ningaraj, Ph.D., MBA, CCRP Senior Director, Scientific Affairs

Currently, there is no targeted treatment available for human respiratory syncytial virus (hRSV) infection beyond supportive care aimed at alleviating symptoms. However, the development of antiviral drugs and effective vaccines is anticipated to play a pivotal role in reducing the global burden of RSV infections. The growing body of RSV research published in leading scientific journals has sparked renewed interest from both large pharmaceutical companies and emerging biotech firms in advancing RSV therapeutics and vaccines. Despite this momentum, the preclinical development of RSV vaccines faces significant challenges, particularly due to the lack of clinically relevant rodent models. Furthermore, ensuring the safety of new vaccine candidates necessitates comprehensive preclinical pharmacological, safety, and toxicology evaluations before entering clinical trials.

Aragen is positioned to support successful IND-enabling preclinical development for RSV therapeutics by offering robust study designs, access to appropriate animal models, and the ability to confirm immunogenicity through both in vivo and in vitro assays. Our scientists are experienced in establishing the identity, purity, safety, and potency of vaccine and antiviral candidates, contributing to their readiness for clinical advancement.

In this white paper, we present multiple case studies utilizing clinically relevant mouse and rat models to evaluate key characteristics of potential RSV therapeutics. These case studies, derived from both internal research and client-sponsored projects conducted over several years, provide clinically meaningful insights that aid in the effective screening and selection of new vaccine and antiviral candidates. Aragen remains committed to supporting RSV therapeutic development by delivering reliable, high-quality preclinical services in this critical area of infectious disease research.